SBFM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	31.81M
Vidutinė apimtis	1.64M
Rinkos kapitalizacija	944 803
EPS	$0 ( 2024-04-02 )
Kita pelno data	( $-8.00 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0130 (1.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Slilaty Steve N.	Buy	100 000	Series B Preferred Stock
2024-02-08	Slilaty Steve N.	Buy	20 000	Series B Preferred Stock
2024-01-26	Beaudoin Marc	Buy	0
2022-11-30	Sebaaly Camille	Buy	30 000	Common Stock
2022-10-20	Chamoun Malek	Sell	0	Common Stock, par value $0.001 per share

INSIDER POWER
100.00
Last 67 transactions
Buy: 1 074 426 098 \| Sell: 315 420 609

Tūris Koreliacija

Ilgas: 0.19 (neutral)

Trumpas: 0.90 (strong)

Signal:(34.554) Same movement expected

Sunshine Biopharma, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sunshine Biopharma, Inc. Koreliacija - Valiuta/Žaliavos

0.79
( moderate )

0.70
( moderate )

0.00
( neutral )

0.72
( moderate )

0.00
( neutral )

0.25
( neutral )

Sunshine Biopharma, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$24.09M
Bruto pelnas:	$8.19M (33.99 %)
EPS:	$-0.190

FY	2023
Pajamos:	$24.09M
Bruto pelnas:	$8.19M (33.99 %)
EPS:	$-0.190

FY	2022
Pajamos:	$4.35M
Bruto pelnas:	$1.70M (39.04 %)
EPS:	$-1.760

FY	2021
Pajamos:	$228 426
Bruto pelnas:	$110 596 (48.42 %)
EPS:	$-0.0609

Financial Reports:

No articles found.

Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.